Plasma metabolomic and lipidomic alterations associated with COVID-19
Di Wu(Chinese PLA General Hospital), Xi Zhou(Wuhan Institute of Virology), Yang Qiu(Beijing Proteome Research Center), Tingju Zhu(International Food Policy Research Institute), Dingyu Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Ting Shu(Chinese Academy of Sciences), Jiqian Xu(Sichuan University), Shuhai Lin(Xiamen University), Jianxin Song(Tongji Hospital), Yu Yuan(Shandong Jianzhu University), Jingfang Mu(Chinese Academy of Sciences), Yongran Wu(Union Hospital), Chengye Yao(Union Hospital), Wen Liu(Chinese Academy of Medical Sciences & Peking Union Medical College), Mingliang Zhang(New York University), Hong Wang(Shanghai University of Traditional Chinese Medicine), Yaxin Wang(Union Hospital), You Shang(Huazhong University of Science and Technology), Muhan Huang(Chinese Academy of Sciences), Xiaobo Yang(Union Hospital), Tang Tang(Westlake University), Qingyu Yang(Chinese Academy of Sciences), Yujie Ren(Wuhan Institute of Virology)
Cited by 367
Related Papers
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
|New England Journal of Medicine|2020|5.5k
RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study
|The Lancet|2021|4.3k
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
SARS-CoV-2 and viral sepsis: observations and hypotheses
|The Lancet|2020|1.2k